These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 33732206)

  • 41. Muscle ultrasound in patients with late-onset Pompe disease identified by newborn screening.
    Jackson DG; Case LE; Huggins E; Holland M; Blount J; Webb LH; Kishnani PS
    Mol Genet Metab Rep; 2023 Sep; 36():100989. PubMed ID: 37670900
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Central nervous system involvement in late-onset Pompe disease: clues from neuroimaging and neuropsychological analysis.
    Musumeci O; Marino S; Granata F; Morabito R; Bonanno L; Brizzi T; Lo Buono V; Corallo F; Longo M; Toscano A
    Eur J Neurol; 2019 Mar; 26(3):442-e35. PubMed ID: 30312517
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Homozygosity for the common GAA gene splice site mutation c.-32-13T>G in Pompe disease is associated with the classical adult phenotypical spectrum.
    Musumeci O; Thieme A; Claeys KG; Wenninger S; Kley RA; Kuhn M; Lukacs Z; Deschauer M; Gaeta M; Toscano A; Gläser D; Schoser B
    Neuromuscul Disord; 2015 Sep; 25(9):719-24. PubMed ID: 26231297
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Respiratory muscle training with enzyme replacement therapy improves muscle strength in late - onset Pompe disease.
    Jevnikar M; Kodric M; Cantarutti F; Cifaldi R; Longo C; Della Porta R; Bembi B; Confalonieri M
    Mol Genet Metab Rep; 2015 Dec; 5():67-71. PubMed ID: 28649546
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD).
    Ripolone M; Violano R; Ronchi D; Mondello S; Nascimbeni A; Colombo I; Fagiolari G; Bordoni A; Fortunato F; Lucchini V; Saredi S; Filosto M; Musumeci O; Tonin P; Mongini T; Previtali S; Morandi L; Angelini C; Mora M; Sandri M; Sciacco M; Toscano A; Comi GP; Moggio M
    Neuropathol Appl Neurobiol; 2018 Aug; 44(5):449-462. PubMed ID: 28574618
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Correlation between quantitative whole-body muscle magnetic resonance imaging and clinical muscle weakness in Pompe disease.
    Horvath JJ; Austin SL; Case LE; Greene KB; Jones HN; Soher BJ; Kishnani PS; Bashir MR
    Muscle Nerve; 2015 May; 51(5):722-30. PubMed ID: 25155446
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Blunted Hypercapnic Respiratory Drive Response in Subjects With Late-Onset Pompe Disease.
    De Vito EL; Monteiro SG; Aruj PK
    Respir Care; 2016 Jul; 61(7):930-5. PubMed ID: 27006351
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Altered activation of the diaphragm in late-onset Pompe disease.
    Smith BK; Corti M; Martin AD; Fuller DD; Byrne BJ
    Respir Physiol Neurobiol; 2016 Feb; 222():11-5. PubMed ID: 26612101
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Diaphragmatic dysfunction in neuromuscular disease, an MRI study.
    Harlaar L; Ciet P; van Tulder G; Brusse E; Timmermans RGM; Janssen WGM; de Bruijne M; van der Ploeg AT; Tiddens HAWM; van Doorn PA; van der Beek NAME
    Neuromuscul Disord; 2022 Jan; 32(1):15-24. PubMed ID: 34973872
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Different Approaches to Analyze Muscle Fat Replacement With Dixon MRI in Pompe Disease.
    Alonso-Jiménez A; Nuñez-Peralta C; Montesinos P; Alonso-Pérez J; García C; Montiel E; Belmonte I; Pedrosa I; Segovia S; Llauger J; Díaz-Manera J
    Front Neurol; 2021; 12():675781. PubMed ID: 34305788
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Trunk muscle involvement in late-onset Pompe disease: study of thirty patients.
    Alejaldre A; Díaz-Manera J; Ravaglia S; Tibaldi EC; D'Amore F; Morís G; Muelas N; Vílchez JJ; García-Medina A; Usón M; Martínez García FA; Illa I; Pichiecchio A
    Neuromuscul Disord; 2012 Oct; 22 Suppl 2():S148-54. PubMed ID: 22980766
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Semi-Automated Analysis of Diaphragmatic Motion with Dynamic Magnetic Resonance Imaging in Healthy Controls and Non-Ambulant Subjects with Duchenne Muscular Dystrophy.
    Bishop CA; Ricotti V; Sinclair CDJ; Evans MRB; Butler JW; Morrow JM; Hanna MG; Matthews PM; Yousry TA; Muntoni F; Thornton JS; Newbould RD; Janiczek RL
    Front Neurol; 2018; 9():9. PubMed ID: 29434565
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Practical Recommendations for Diagnosis and Management of Respiratory Muscle Weakness in Late-Onset Pompe Disease.
    Boentert M; Prigent H; Várdi K; Jones HN; Mellies U; Simonds AK; Wenninger S; Barrot Cortés E; Confalonieri M
    Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27763517
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Imaging respiratory muscle quality and function in Duchenne muscular dystrophy.
    Barnard AM; Lott DJ; Batra A; Triplett WT; Forbes SC; Riehl SL; Willcocks RJ; Smith BK; Vandenborne K; Walter GA
    J Neurol; 2019 Nov; 266(11):2752-2763. PubMed ID: 31350642
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Enzymatic replacement therapy in patients with late-onset Pompe disease - 6-Year follow up.
    Witkowski G; Konopko M; Rola R; Ługowska A; Ryglewicz D; Sienkiewicz-Jarosz H
    Neurol Neurochir Pol; 2018 Aug; 52(4):465-469. PubMed ID: 29803406
    [TBL] [Abstract][Full Text] [Related]  

  • 56. 2-deoxy-2-[18]fluoro-D-glucose PET/CT (18FDG PET/CT) may not be a viable biomarker in Pompe disease.
    Plöckinger U; Prasad V; Ziagaki A; Tiling N; Poellinger A
    Hum Genomics; 2018 Mar; 12(1):14. PubMed ID: 29523196
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Clinical sequelae of 17 cases with glycogen storage disease type II/Pompe disease].
    Zhang HB; Zhang WM; Qiu JJ; Meng Y; Qiu ZQ
    Zhonghua Er Ke Za Zhi; 2012 Jun; 50(6):415-9. PubMed ID: 22931935
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Observational clinical study of 22 adult-onset Pompe disease patients undergoing enzyme replacement therapy over 5years.
    Stepien KM; Hendriksz CJ; Roberts M; Sharma R
    Mol Genet Metab; 2016 Apr; 117(4):413-8. PubMed ID: 26873529
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Muscle MRI as a biomarker of disease activity and progression in myotonic dystrophy type 1: a longitudinal study.
    Fionda L; Leonardi L; Tufano L; Lauletta A; Morino S; Merlonghi G; Costanzo R; Rossini E; Forcina F; Marando D; Sarzi Amadè D; Bucci E; Salvetti M; Antonini G; Garibaldi M
    J Neurol; 2024 Sep; 271(9):5864-5874. PubMed ID: 38972019
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inspiratory pressure-generating capacity is preserved during ventilatory and non-ventilatory behaviours in young dystrophic mdx mice despite profound diaphragm muscle weakness.
    Burns DP; Murphy KH; Lucking EF; O'Halloran KD
    J Physiol; 2019 Feb; 597(3):831-848. PubMed ID: 30570134
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.